Title: O Crandell Addington: Innovator in Cancer Therapeutics
Introduction
O Crandell Addington is a notable inventor in the field of cancer therapeutics. He has made significant contributions to the understanding of how cardiac glycosides can be utilized in cancer treatment. His work focuses on developing methods to predict therapeutic responses in patients undergoing chemotherapy.
Latest Patents
O Crandell Addington holds a patent titled "Method Of Determining The Probability Of A Therapeutic Response In Cancer Chemotherapy With Cardiac Glycoside." This patent describes a prognostic assay and kit designed to assess the likelihood of a diseased cell or tissue responding to treatment with a cardiac glycoside. The kit and assay determine the ratio of isoforms of the alpha subunit of Na, K-ATPase obtained from the diseased cell or tissue. This innovative approach can predict the therapeutic responsiveness of cancer or tumors to treatment with cardiac glycosides.
Career Highlights
O Crandell Addington is associated with Phoenix Biotechnology, Inc., where he continues to advance research in cancer treatment. His work has been instrumental in developing new methodologies that enhance the effectiveness of chemotherapy for patients with excessive cell proliferation.
Collaborations
He has collaborated with notable colleagues such as Robert A Newman and Peiying Yang, contributing to the advancement of cancer therapeutics through shared expertise and innovative research.
Conclusion
O Crandell Addington's contributions to cancer treatment through his innovative patent and collaborative efforts highlight his commitment to improving therapeutic outcomes for patients. His work continues to pave the way for advancements in the field of oncology.